The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced it has entered into a compounding agreement with a U.S.-based 503A sterile compounding pharmacy for prescription-based preparation and fulfillment of peptide products, including BPC-157.

Under the agreement, all peptides will be compounded in the United States in accordance with regulatory requirements governing 503A sterile compounding pharmacies. The compounding partner will provide access to infrastructure with capacity to fulfill up to approximately 25,000 prescriptions per day across all U.S. states.

Compounding activities are expected to commence June 1, 2026, following completion of onboarding and integration between the parties. The company did not disclose the identity of the compounding partner for competitive reasons.

"We're excited to have signed this agreement — it's a significant step forward for the Company," said Pratap Sandhu, CEO. "The part that matters most to us is that every prescription under the agreement will be 100% compounded in the United States."

The agreement comes as the FDA removed several peptides, including BPC-157, from Category 2 of its 503A bulk drug substances framework and referred them to the Pharmacy Compounding Advisory Committee for evaluation. The committee is scheduled to review BPC-157 and other peptide substances at a public meeting July 23, 2026.

Separately, the company issued 300,000 common shares at a deemed price of $0.42 per share to settle $125,000 in outstanding debt owed to its CEO. The shares are subject to a four-month hold period plus one day from the date of issuance.